Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring : recommendations for a public health approach

Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring recommendations for a public health approach

Detalles Bibliográficos
Autor principal: World Health Organization (author)
Autor Corporativo: World Health Organization, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Geneva : World Health Organization [2021]
Edición:1st ed
Materias:
Antiretroviral agents.
HIV infections > Prevention.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009624054006719
Tabla de Contenidos:
  • Foreword
  • Abbreviations and acronyms
  • ACKNOWLEDGEMENTS
  • Executive summary
  • Summary recommendations
  • INTRODUCTION
  • 1.1 Background and rationale
  • 1.2 Objectives
  • 1.3 Target audience
  • 1.4 Guiding principles
  • 1.5 Methods for developing the guidelines
  • 1.6 Organization of the guidelines
  • HIV TESTING AND DIAGNOSIS
  • 2.1 Introduction
  • 2.2 HIV testing for a changing epidemic
  • 2.3 Mobilizing demand and pre-test services
  • 2.4 HIV testing service delivery approaches
  • 2.5 Post-test services and linkage to prevention, treatment and other services
  • 2.6 Strategies to make HIV testing services accessible
  • 2.7 Maintaining the accuracy and reliability of HIV diagnosis
  • 2.8 HIV diagnosis among infants and children
  • HIV prevention
  • 3.1 Combination HIV prevention
  • 3.2 Pre-exposure prophylaxis for preventing the acquisition of HIV
  • 3.3 Post-exposure prophylaxis
  • 3.4 Infant prophylaxis
  • ANTIRETROVIRAL THERAPY
  • 4.1 Introduction
  • 4.2 Preparing people living with HIV for ART
  • 4.3 What to expect in the first months of ART
  • 4.4 When to start ART
  • 4.5 Timing of ART
  • 4.6 What to start
  • 4.7 Monitoring the response to ART
  • 4.8 Monitoring ARV toxicity
  • 4.9 ARV drug resistance
  • 4.10 Key ARV drug interactions
  • Managing advancedHIV disease
  • 5.1 Introduction
  • 5.2 Causes of morbidity and mortality among adults with advanced HIV disease
  • 5.3 Providing a package of care
  • 5.4 Overview of clinical management of cryptococcal disease
  • 5.5 Overview of clinical management of histoplasmosis
  • 5.6 Advanced HIV disease among children and adolescents
  • 5.7 Supporting decision-making for providing a packageof care
  • 5.8 Programme considerations
  • GENERAL CARE AND MANAGING COMMON COINFECTIONS AND COMORBIDITIES
  • 6.1 Introduction
  • 6.2 General care for people living with HIV
  • 6.3 Co-trimoxazole prophylaxis.
  • 6.4 Tuberculosis
  • 6.5 Hepatitis B and C
  • 6.6 Malaria
  • 6.7 Buruli ulcer
  • 6.8 Leishmaniasis
  • 6.9 Cervical cancer
  • 6.10 Noncommunicable diseases
  • 6.11 Mental health among people living with HIV
  • 6.12 Drug use
  • 6.13 Sexually transmitted infections
  • 6.14 Vaccines for people living with HIV
  • 6.15 HIV-related skin and oral conditions
  • 6.16 Nutritional care and support
  • 6.17 Palliative care
  • 6.18 Noncommunicable diseases among children and adolescents
  • SERVICE DELIVERY
  • 7.1 Introduction
  • 7.2 Linkage from HIV testing to enrolment in care
  • 7.3 Differentiated service delivery for HIV treatment
  • 7.4 People-centred care
  • 7.5 Initiating and maintaining treatment
  • 7.6 Continuity of care
  • 7.7 Task sharing
  • 7.8 Decentralization
  • 7.9 Integrating services
  • 7.10 Delivering HIV services to children
  • 7.11 Service delivery for adolescents
  • 7.12 Improving the quality of HIV care services
  • 7.13 Procurement and supply management systems for HIV health products
  • 7.14 Laboratory and diagnostic services
  • 7.15 Laboratory connectivity
  • MONITORING ART PROGRAMME FUNCTIONING
  • 8.1 Introduction
  • 8.2 Selection of key indicators to improve service delivery and assess impact
  • 8.3 Data collection and disaggregation
  • 8.4 Strengthening data systems
  • 8.5 Evaluation, including impact and programme performance
  • 8.6 Monitoring ARV drug toxicity
  • 8.7 HIV drug resistance
  • Publication, dissemination and evaluation
  • 9.1 Publication
  • 9.2 Dissemination and implementation
  • 9.3 Useful analytical tools for planning
  • 9.4 Evaluation
  • Glossary
  • ANNEX 1: DOSAGES FOR ARV DRUGS
  • Annex 2: key drug interactions
  • for aRVs
  • 1.1 Background and rationale
  • 1.2 Objectives
  • 1.3 Target audience
  • 1.4 Guiding principles
  • 1.5 Methods for developing the guidelines
  • 1.6 Organization of the guidelines.
  • 2.1 Introduction
  • 2.2 HIV testing for a changing epidemic
  • 2.3 Mobilizing demand and pre-test services
  • 2.4 HIV testing service delivery approaches
  • 2.5 Post-test services and linkage to prevention, treatment and other services
  • 2.6 Strategies to make HIV testing services accessible
  • 2.7 Maintaining the accuracy and reliability of HIV diagnosis
  • 2.8 HIV diagnosis among infants and children
  • 3.1 Combination HIV prevention
  • 3.2 Pre-exposure prophylaxis for preventing the acquisition of HIV
  • 3.3 Post-exposure prophylaxis
  • 3.4 Infant prophylaxis
  • 4.1 Introduction
  • 4.2 Preparing people living with HIV for ART
  • 4.3 What to expect in the first months of ART
  • 4.4 When to start ART
  • 4.5 Timing of ART
  • 4.6 What to start
  • 4.7 Monitoring the response to ART
  • 4.8 Monitoring ARV toxicity
  • 4.9 ARV drug resistance
  • 4.10 Key ARV drug interactions
  • 5.1 Introduction
  • 5.2 Causes of morbidity and mortality among adults with advanced HIV disease
  • 5.3 Providing a package of care
  • 5.4 Overview of clinical management of cryptococcal disease
  • 5.5 Overview of clinical management of histoplasmosis
  • 5.6 Advanced HIV disease among children and adolescents
  • 5.7 Supporting decision-making for providing a packageof care
  • 5.8 Programme considerations
  • 6.1 Introduction
  • 6.2 General care for people living with HIV
  • 6.3 Co-trimoxazole prophylaxis
  • 6.4 Tuberculosis
  • 6.5 Hepatitis B and C
  • 6.6 Malaria
  • 6.7 Buruli ulcer
  • 6.8 Leishmaniasis
  • 6.9 Cervical cancer
  • 6.10 Noncommunicable diseases
  • 6.11 Mental health among people living with HIV
  • 6.12 Drug use
  • 6.13 Sexually transmitted infections
  • 6.14 Vaccines for people living with HIV
  • 6.15 HIV-related skin and oral conditions
  • 6.16 Nutritional care and support
  • 6.17 Palliative care
  • 6.18 Noncommunicable diseases among children and adolescents.
  • 7.1 Introduction
  • 7.2 Linkage from HIV testing to enrolment in care
  • 7.3 Differentiated service delivery for HIV treatment
  • 7.4 People-centred care
  • 7.5 Initiating and maintaining treatment
  • 7.6 Continuity of care
  • 7.7 Task sharing
  • 7.8 Decentralization
  • 7.9 Integrating services
  • 7.10 Delivering HIV services to children
  • 7.11 Service delivery for adolescents
  • 7.12 Improving the quality of HIV care services
  • 7.13 Procurement and supply management systems for HIV health products
  • 7.14 Laboratory and diagnostic services
  • 7.15 Laboratory connectivity
  • 8.1 Introduction
  • 8.2 Selection of key indicators to improve service delivery and assess impact
  • 8.3 Data collection and disaggregation
  • 8.4 Strengthening data systems
  • 8.5 Evaluation, including impact and programme performance
  • 8.6 Monitoring ARV drug toxicity
  • 8.7 HIV drug resistance
  • 9.1 Publication
  • 9.2 Dissemination and implementation
  • 9.3 Useful analytical tools for planning
  • 9.4 Evaluation
  • Foreword
  • Abbreviations and acronyms
  • ACKNOWLEDGEMENTS
  • Executive summary.

Ejemplares similares